Researchers have uncovered a new way to attack lymphoma by targeting a non-catalytic region of a key regulatory enzyme, rather than its traditional active site. Researchers at VCU Massey Comprehensive ...

Lyell Immunopharma, Inc. has announced plans to accelerate the development of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell therapy for aggressive large B-cell lymphoma, with pivotal trials expected ...

Some forms of blood cancer, such as multiple myeloma and lymphoma, are malignant diseases that originate from immune cells, specifically lymphocytes. In recent years, CAR-T cell therapies have become ...

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...

Translocations are chromosomal “cut and paste” errors that drive many lymphomas, a type of blood cancer and the sixth most common form of cancer overall. This includes mantle cell lymphoma, a rare but ...

Researchers used RBF4, a compound chemically identical to an FDA-approved heart medication, to target lymphoma. In ...

The FDA has removed R/R PCNSL from a Limitations of Use section on the CAR-T product’s label based on positive findings from ...

New study shows DNA’s 3D structure helps prevent lymphoma by keeping tumor suppressor genes active. Cancer isn’t just driven by genetic mutations - it also stems from structural breakdowns within the ...